Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients

Table 2

Virologic response during and after treatment.

	Regimen 1 (); Sofosbuvir + ribavirin + peg IFN for 12 weeks	Regimen 2 (); Sofosbuvir + ribavirin for 24 weeks
Mean HCV PCR baseline (IU/mL)	5,377,975	13,897,828
During treatment
Week 4
HCV RNA < 30 IU/mL	25 (100%)	9 (81%)
End of treatment
HCV RNA undetectable	25 (100%)	11 (100%)
After treatment
Week 12	(25/25) 100%	(6/9) 75%^∧

Three patients did not complete follow-up period yet.
Two patients relapsed and one deceased while on sofosbuvir therapy.
Virologic relapse was defined as a confirmed HCV RNA level of 25 IU per milliliter or more between the final visit and 12 weeks after the last dose of study drugs among patients who had an HCV RNA level of less than lower limit of quantification (LLOQ) at the final visit.